Search
EHA-ISHBT Hematology Tutorial 2020
The 4th EHA-ISHBT Hematology Tutorial on Hematological Disorders was held on February 28 and 29 in Chandigarh, India, and chaired by Prof John Gribben, Prof Neelam Varma and Prof Pankaj Malhotra.
Read more2018’s Sjöberg Prize awarded for unique treatment that cures a once fatal cancer
Dr. Zhu Chen, Dr. Anne Dejean and Dr. Hugues de Thé will be awarded the Sjöberg Prize 2018 for their work on how acute promyelocytic leukemia (APL) could be cured based on arsenic and retinoic acid.
Read moreThe EHA Guidelines Workshop, a meaningful and successful first Series!
November 2020 – April 2021
In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series.
Lymphomas from A to Z
Nineteen countries from 3 continents were represented during the EHA-SWG Scientific Meeting on Rare Lymphomas on March 10-12, 2017 in Barcelona, Spain.
Read morePress release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013
In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.
Read moreA Special Coach for the Cantera 2024
A unique tutorial for young hematologists, co-sponsored by the EHA Lymphoma Group and the Fondazione Italiana Linfomi. DatesMay 14 to May 17, 2024. LocationLecce, Italy. TopicHow the utilization of cellular therapy strategies looks for lymphomas in 2024.
Read moreEHA25 Virtual | News Room
Welcome to the news room of EHA25 Virtual where you can find the most relevant news items.
Read moreEHA-Baltic Hematology Tutorial in Estonia provides European-level expertise to local hematologists
EHA partnered with three Baltic societies on October 18 and 19 to provide European-level expertise to local hematology trainees and experienced hematologists.
Read moreFDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement
We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- »